STOCK TITAN

Zai Lab Limited - ZLAB STOCK NEWS

Welcome to our dedicated news page for Zai Lab (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zai Lab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zai Lab's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
-
-
Zai Lab Limited

Nasdaq:ZLAB

ZLAB Rankings

ZLAB Stock Data

1.59B
887.18M
1.82%
44.72%
3.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Shanghai

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve